Moderna, Inc.
320 Bent Street
Cambridge
Massachusetts
02141
United States
Tel: 617-714-6500
Fax: 617-583-1998
Website: http://www.modernatx.com/
Email: info@modernatx.com
About Moderna, Inc.
At Moderna, we are pioneering the development of a new class of drugs made of messenger RNA (mRNA). This novel drug platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest, from native proteins to antibodies and other entirely novel protein constructs that can have therapeutic activity inside and outside of cells.
We have a clear mission to propel the field of mRNA science forward and deliver new medicines to patients and a unique vision for how to achieve this mission.
Our Mission: Deliver on the promise of mRNA science to create a new generation of transformative medicines for patients.
Our Vision: Unlock the potential of mRNA Therapeutics™ by establishing an ecosystem of teams and partners that will work together to develop the broadest possible array of drugs, across diverse therapeutic areas and routes of administration, for serious diseases that are not treatable today.
144 articles with Moderna, Inc.
-
Moderna to Present at Goldman Sachs 40th Annual Global Healthcare Conference
6/7/2019
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Stephane Bancel, Chief Executive Officer, and Lorence Kim, M.D., Chief Financial Officer, will present at the Goldman Sachs 40th Annual Global Healthcare Conference
-
Moderna Announces Presentation of Interim Data from Phase 1 Study of mRNA Personalized Cancer Vaccine at 2019 ASCO Annual Meeting
6/1/2019
Moderna, Inc. announced interim data from an ongoing Phase 1 clinical study in patients with both resected (adjuvant) and unresected (advanced) solid tumors.
-
Moderna Announces Publication of Preclinical Data for Chikungunya Antibody Program
5/17/2019
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the publication of preclinical data in Science Immunology, showing that mRNA encoding a human monoclonal antibody against the chikungunya virus delivered in a proprietary lipid nanoparticle (LNP) can protect from infection by the virus in vivo.
-
Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.
-
Cambridge, Mass.-based Moderna announced publication of results from two Phase I clinical trials of mRNA vaccines against two strains of influenza, H10N8 and H7N0. They were both published in the journal Vaccine.
-
Moderna Announces Publication of Phase 1 Data for mRNA Vaccines Against Two Potential Pandemic Influenza Strains
5/10/2019
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the publication of results from two Phase 1 clinical studies showing that mRNA vaccines against H10N8 and H7N9 influenza viruses were well-tolerated and elicited robust immune responses.
-
Moderna Reports First Quarter 2019 Financial Results and Provides Business Updates
5/8/2019
Rare Diseases: New development candidate announced for glycogen storage disease type 1a (GSD1a), a rare metabolic disorder; Company now has five rare disease programs in its pipeline
-
Moderna to Present at Bank of America Merrill Lynch 2019 Health Care Conference
5/6/2019
Moderna, Inc. announced that Tal Zaks, M.D., Ph.D., Chief Medical Officer, and Lorence Kim, M.D., Chief Financial Officer, will present at the Bank of America Merrill Lynch 2019 Health Care Conference on Tuesday, May 14, 2019 at 9:20 a.m. PT.
-
The annual meeting of the American Society of Gene & Cell Therapy (ASGCT) was held in Washington, DC this week, with literally hundreds of abstracts and presentations. Here’s a look at some of the highlights.
-
Moderna to Present Preclinical Data at 2019 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
4/29/2019
The Company and academic collaborators to share data from seven preclinical studies demonstrating the potential of mRNA-based therapies to treat rare metabolic and genetic disorders
-
Moderna to Host Science Day on May 7, 2019 and Report First Quarter Financial Results on May 8, 2019
4/16/2019
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host its annual Science Day for analysts and investors on Tuesday, May 7, 2019 at 8:00 a.m. ET in Cambridge, MA.
-
Moderna to Present at 18th Annual Needham Healthcare Conference
4/3/2019
Moderna, Inc. announced that Tal Zaks, M.D., Ph.D., Moderna’s Chief Medical Officer, will participate in a fireside chat at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, 2019 at 11:20 a.m. ET.
-
Coming off its record-breaking initial public offering (IPO) in December, where it raised $604.3 million, Moderna released its fourth-quarter financials, outlining an ambitious company buzzing with activity.
-
Moderna to Present at Upcoming Investor Conferences in March
3/4/2019
Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines to create a new generation of transformative medicines for patients, announced its participation in the following upcoming investor conferences:
-
Evaluate recently published the Vantage Pharma, Biotech and Medtech 2018 in review report. The annual report offers insights into the previous year’s activities in biopharma and the medical device industry.
-
Moderna to Report Fourth Quarter and Full Year 2018 Financial Results on Wednesday, March 6, 2019
2/21/2019
Moderna, Inc. announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, March 6, 2019 to report its fourth quarter and full year 2018 financial results and provide a corporate update.
-
Phase 1 Data Published in Nature Communications Show Potential of mRNA Encoding VEGF-A as a Regenerative Therapeutic
2/20/2019
AZD8601 now in an ongoing Phase 2a study with patients receiving epicardial injections of VEGF-A mRNA during coronary artery bypass grafting surgery
-
Moderna Announces Positive Interim Phase 1 Data for First Combination Vaccine Against the Respiratory Viruses hMPV and PIV3
2/12/2019
Interim data show vaccination with mRNA-1653 boosted serum neutralization titers against hMPV and PIV3 at all dose levels tested and was generally well tolerated
-
Moderna Announces Dosing of the First Monoclonal Antibody Encoded by mRNA in a Clinical Trial
2/5/2019
Antibody against Chikungunya virus (mRNA-1944) is the first development candidate from Moderna’s systemic therapeutics modalities to start human dosing
-
Messenger RNA (mRNA) is a family of RNA molecules that transport genetic information from DNA to the ribosome, where it specifies the amino acid sequence that creates proteins. In theory, by coding your own mRNA, it should be possible to insert it into the cells and turn them into protein factori...